Minnesota Eye Consultants PA

PLEASANTON, Calif.--(BUSINESS WIRE)-- RadiusXR, the trailblazer in Digital Health, announces the publication of its groundbreaking NOVA Clinical Trial in Translational Vision Science and Technology (TVST), a prestigious journal by the Association for Research in Vision and Ophthalmology (ARVO). This milestone publication confirms RadiusXR's unwavering commitment to advancing ocular health and heralds a new era in visual field testing. This press release features multimedia. View the full release here: All-inclusive RadiusXR Heath Tech Platform (Photo: Business Wire) The NOVA Clinical Trial has revealed remarkable findings, including statistical non-inferiority to current clinical standards for sensitivities at individual test locations, glaucoma staging using Medicare definitions, and an exceptionally high correlation of 0.94 in mean deviation.1 These results underscore the unparalleled accuracy and reliability of RadiusXR's approach to visual field testing for head-mounted virtual reality perimetry. Moreover, unlike other virtual reality perimeters (VRPs), RadiusXR measures vision within the photopic range, aligning with existing visual field platforms' standards. This alignment enables consistent clinical training and facilitates comparison to patients' prior examinations, as normative databases and mean deviation/pattern standard deviation (MD/PSD) plots are based on the photopic range. RadiusXR's steadfast adherence to industry standards ensures seamless integration into clinical practice and enhances patient care. "The publication of the NOVA Clinical Trial in TVST reaffirms RadiusXR's position as the leader in visual field testing innovation," remarked Ammad Khan, RadiusXR's Chief Executive Officer. “Our proprietary technology, combined with spatial computing, delivers unparalleled accuracy and precision, revolutionizing the diagnosis and management of ocular conditions." Dr. Thomas Samuelson, a distinguished ophthalmologist at Minnesota Eye Consultants in Minneapolis, expressed, "The findings from the NOVA Clinical Trial are truly groundbreaking. RadiusXR's innovative approach to visual field testing represents a significant advancement in the field of ophthalmology. This technology can potentially revolutionize how we diagnose and manage ocular conditions, ultimately improving patient outcomes and quality of life." In July 2023, RadiusXR announced it entered into a collaboration and marketing agreement with Glaukos Corporation, a leading ophthalmic pharmaceutical and medical technology company, whereby Glaukos became the exclusive sales agent to market, promote, and solicit orders for RadiusXR in the United States. Radius continues to lead development and commercialization efforts for RadiusXR. The complete details of the NOVA Clinical Trial are available here > For more information about RadiusXR and its advanced technologies, please visit radiusxr.com About RadiusXR: The RadiusXR ( ) platform is a revolutionary portable vision diagnostic and patient engagement system. It combines medical-grade diagnostics, business management tools, and patient education resources within a wearable spatial computing device. The RadiusExam® and proprietary algorithms provide diagnostic testing results equivalent to current gold standards demonstrated through a clinical trial that shows statistical noninferiority of estimated sensitivities compared to SITA-Standard. This comprehensive digital health platform combines proprietary hardware and software to empower medical professionals to diagnose patients accurately, enhance patient engagement, and reduce staff workload. It enables patients to perform self-guided vision exams with minimal supervision, thereby aiding in the growth of eye care practices. About Glaukos: Glaukos ( ) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases. 1Chris Bradley, Iqbal Ike K. Ahmed, Thomas W. Samuelson, Michael Chaglasian, Howard Barnebey, Nathan Radcliffe, Jason Bacharach; Validation of a Wearable Virtual Reality Perimeter for Glaucoma Staging, The NOVA Trial: Novel Virtual Reality Field Assessment. Trans. Vis. Sci. Tech. 2024;13(3):10. .

With over 40 years of ophthalmology industry experience, Dr. Lindstrom will lead Surface Ophthalmics into its next stage of growth as it advances its innovative and patented proprietary portfolio for dry eye syndrome. PLEASANTON, Calif.--(BUSINESS WIRE)-- Surface Ophthalmics, a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman. A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A. Dr. Lindstrom will lead in partnership with Surface’s distinguished Board of Directors including Adrienne Graves, Ph.D., (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley. In the US alone, an estimated 38 million people have some form of DES, yet only 17 million are diagnosed and fewer still, 1.7 million, are using a prescription therapy.1,2 With its product portfolio in development, Surface seeks to address the full range of DES, from episodic to chronic by providing eye care professionals targeted therapies to treat the signs, symptoms, and underlying causes of DES, which can be naturally occurring or following ocular surgery.3 “I am honored and thrilled to lead Surface Ophthalmics into its next phase of expansion as we work to advance the company’s innovative and proprietary medicinal candidates for patients suffering from DES,” said Dr. Lindstrom. “Our solutions hold significant potential to meet existing gaps in care, and I’m eager to collaborate with our talented team to introduce these products to the market.” Surface Ophthalmics is advancing two products: Kera Sol™ Tears, an over-the-counter artificial tear solution designed for cell-compatible, short-term, fast-acting, temporary relief of burning and irritation caused by dryness of the eye. Additionally, the company is progressing the clinical program for its investigational drug, Mycosol (Surf-101), a first-in-class prescription eye drop that delivers Mycophenolate in Surface’s proprietary formulation. This combination is designed to provide sustained immunosuppressive action and mucin upregulation at the ocular surface. Richard Lindstrom, MD Dr. Richard Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. Dr. Lindstrom has served as a researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon in the ophthalmology field. Dr. Lindstrom has served as associate director of the Minnesota Lions Eye Bank from 1987 - 2017. He is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several public and privately held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery from 1993 to 1994, the International Intraocular Implant Society from 2002 to 2004, the International Refractive Surgery Club from 2002 to 2004, and the American Society of Cataract and Refractive Surgery from 2007 to 2008. He currently serves on the ASCRS Executive Committee and is a past chair of the ASCRS Foundation. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently an adjunct professor and foundation trustee emeritus. Dr. Lindstrom also chaired the Ophthalmology and Visual Neurosciences Foundation for three decades. About Surface Ophthalmics Surface Ophthalmics is a pioneering biopharmaceutical firm dedicated to the discovery and market introduction of novel treatments for diseases affecting the ocular surface. Our mission is to address critical unmet needs in eye care by harnessing in-depth expertise, a dynamic strategy, operational efficiency, and distinctive clinical advantages. To learn more visit and follow us on LinkedIn. References 1 2019 Dry Eye Products Market Report, Market Scope 2 Symphony Rx Data divided by DES Prevalence Study and validated with Market Scope data 3 Craig JP, et al., TFOS DEWS II Report Executive Summary, The Ocular Surface (2017)

BERWYN, Pa.--(BUSINESS WIRE)-- Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED). This acquisition unites Nordic Pharma's pharmaceutical expertise, with Visant's FDA-cleared hyaluronic acid derivative LACRIFILL® canalicular occlusive device, which is intended to temporarily block tear drainage by the occlusion of the canalicular system. Nordic Pharma will launch and commercialize LACRIFILL in the U.S. and has been chosen because of its focus on Ophthalmology. This acquisition will enhance Nordic Pharma’s impact on the global ophthalmology market starting with the U.S. launch of LACRIFILL, the patented therapy for DED. “Visant is thrilled to be joining the Nordic Pharma group,” said Vartan Ghazarossian, Ph.D., Visant co-founder and CEO. “Our team has been passionate about bringing a truly innovative solution to patients suffering from DED and we are excited to be joining the Nordic Pharma team as we begin our commercialization efforts.” This is the second branded medical device Nordic Pharma will introduce in the U.S. and is a complementary fit to the lead brand. Following the anticipated 2024 U.S. launch of LACRIFILL, Nordic Pharma intends to seek regulatory approval to make the product available globally. “We’re ecstatic Visant Medical selected Nordic Pharma as their partner and for the opportunity to introduce LACRIFILL to the ophthalmologists and optometrists treating the over 16 million people diagnosed with DED in the U.S.,” said Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma brand. “LACRIFILL represents an innovative and elegant form factor to occlude that should become the gold standard for preoperative patient care for those with DED.” LACRIFILL is indicated for dry eye conditions and provides relief for the symptoms of dry eye. It has received FDA 510(k) clearance and has an established CPT reimbursement code. These benefits make LACRIFILL appealing to both patients and providers. Richard Lindstrom, MD, Founder and Attending Surgeon Emeritus at Minnesota Eye Consultants said, “LACRIFILL is set to play a useful role in treating patients with the signs and symptoms of dry eye, especially prior to refractive corneal or cataract surgery. LACRIFILL will provide the Eye Care Professional with a new and attractive option to treat patients with Dry Eye Disease within their practice.” Paul Karpecki, OD, Associate Professor, University of Pikeville, Kentucky College of Optometry; Kentucky Eye Institute; emphasized the benefits of using LACRIFILL, stating: "A gel, consisting of cross-linked hyaluronic acid represents a significant impact in ocular health in tear conservation. The properties of the hyaluronic acid in a canalicular filler offer unique comfort and effectiveness in managing dry eye symptoms.” Raymond James & Associates, Inc. served as exclusive financial advisor to Visant Medical, Inc. and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal advisor. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as legal advisor to Amring Pharmaceuticals Inc. About Nordic Group B.V. Nordic Pharma is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Ophthalmology, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide. Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies. About Amring Pharmaceuticals Inc. Amring Pharmaceuticals Inc., subsidiary of Nordic Group B.V., is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market. Amring is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace. About Visant Medical, Inc. Based in Menlo Park, CA, Visant Medical is a clinical-stage medical device company. It received FDA 510(k) clearance in 2022 for LACRIFILL® cross-linked hyaluronic acid-based canalicular occlusive device. LACRIFILL is intended to block tear drainage by occlusion of the canalicular system. It is indicated for use, for up to 6 months, in patients experiencing dry eye symptoms. Symatese SAS, a French company based in Lyon, was instrumental in the development of LACRIFILL, significantly enhancing the product's design and performance, by leveraging its expertise in tissue regeneration, reconstruction and related delivery systems. SYMATESE specializes in injectable crosslinked HA gels for many markets including Aesthetic, Rheumatology, Ophthalmology. With more than 40 researchers, SYMATESE designs the most advanced medical device solutions thanks to their technology portfolio in hyaluronic acid, collagen, thermoplastics and silicone. Safe Harbor This press release contains forward-looking statements, including, without limitation, statements related to Amring/Nordic Pharma’s business developments and the implementation of Amring/Nordic Pharma’s strategic initiatives. Because these statements reflect Amring/Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Amring/Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Amring/Nordic Pharma, and other factors that could affect Amring/Nordic Pharma’s business and financial performance. Amring/Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.